CompletedNot Applicable

Low Plasma Mannose Binding Lectin (p-MBL) Level is a Risk Factor for Recurrent Pregnancy Loss (RPL)

Denmark452 participantsStarted 2016-01-01

Plain-language summary

The present study is based on the hypothesis, that recurrent pregnancy loss (RPL) is associated with abnormal plasma mannose binding lectin (p-MBL) level. Secondarily, p-MBL level may affect the reproductive and the perinatal outcome in the first pregnancy following RPL. Thus, the present study aim to examine whether MBL should be a biomarker for women at risk for RPL and, secondarily, affect the reproductive and perinatal outcome, and thereby help clinicians identify fragile women who need intensified perinatal care.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Women admitted to the Centre for Recurrent Pregnancy Loss of Western Denmark January 2016 to March 2020 Exclusion Criteria: * Less than 3 consecutive pregnancy losses * Significant uterine malformation on hydrosonography or hysteroscopy * Significant chromosomal abnormalities * Abnormal menstrual cycle length (\<22 or \>35 days) or irregular cycle * Pregnancy at first meeting in the Recurrent Miscarriage Clinic * Age \<18 and \>45 years

What they're measuring

Plasma MBL Level (ug/ml)

Timeframe: At first consultation. Results accessible within 3 weeks.

Trial details

NCT IDNCT04017754

SponsorAalborg University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-03-29

Results submitted2021-01-05

View on ClinicalTrials.gov More Recurrent Miscarriage trials